



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 19, 2009

To: Primary Clinical Research Associates

From: Alicia Elsing
Protocol Development Coordinator

Re: N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

The End of Active Treatment Form has been revised as follows:

- In order to match the electronic form, “complete event monitory form” was removed as an instruction for Reason #4 on the paper form.

If you have any questions, please feel free to contact me at 507/538-3893.

Enclosure